FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
This article was originally published in The Tan Sheet
Executive Summary
WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status